Ataluren for Nonsense Mutation in CDKL5 and Dravet Syndrome
Study Details
Study Description
Brief Summary
This is a phase 2, crossover study of Ataluren for the treatment of nonsense mutation Dravet syndrome or cyclin-dependent kinase-like 5 (CDKL5) deficiency, resulting in drug-resistant epilepsy. Patients will receive 12 weeks of ataluren or placebo during each treatment period. Treatment Period 1 will be followed by a 4-week Washout Period. Based on ataluren PK and pharmacodynamic data, the 4-week washout period is deemed an appropriate length of time to eliminate any ataluren drug effects. Following the Washout Period, patients will crossover to receive the opposite treatment during Treatment Period 2 as follows: Patients receiving ataluren during Treatment Period 1 will receive placebo during Treatment Period 2. Patients receiving placebo during Treatment Period 1 will receive ataluren during Treatment Period 2.
| Condition or Disease | Intervention/Treatment | Phase |
|---|---|---|
|
Phase 2 |
Detailed Description
Investigators will try to characterize the safety profile of ataluren in patients with CDKL5 or Dravet syndrome resulting from a nonsense mutation and evaluate changes in convulsive and/or drop seizure frequency from Baseline following ataluren treatment in patients with CDKL5 or Dravet syndrome resulting from a nonsense mutation. Investigators will measure changes in minor seizure types (absence, myoclonic, complex partial/focal dyscognitive) following ataluren treatment in patients with CDKL5 or Dravet syndrome resulting from a nonsense mutation and changes from Baseline in cognitive, motor, and behavioral function as well as QOL following ataluren treatment in patients with CDKL5 or Dravet syndrome resulting from a nonsense mutation.
Study Design
Arms and Interventions
| Arm | Intervention/Treatment |
|---|---|
| Active Comparator: Ataluren Followed By Placebo Cross Over Design: Treatment Period 1 with Ataluren (Week 0/Day 1 to Week 12), Washout Period (Week 12 to Week 16), crossover to Placebo Treatment Period 2 (Week 16 to Week 28), and Follow-up (Week 28 to Week 32). |
Drug: ataluren
Powder formulation
Other Names:
Drug: Placebo
Powder formulation
|
| Active Comparator: Placebo Followed by Ataluren Treatment Period 1 with Placebo (Week 0/Day 1 to Week 12), Washout Period (Week 12 to Week 16), crossover to Treatment Period 2 with Ataluren(Week 16 to Week 28). |
Drug: ataluren
Powder formulation
Other Names:
Drug: Placebo
Powder formulation
|
Outcome Measures
Primary Outcome Measures
- Number of adverse events and serious adverse events related to ataluren [Baseline to 3 months]
- Number of adverse events and serious adverse events related to ataluren [3 months to 6 months]
- Number of adverse events and serious adverse events related to ataluren [6 months to 1 year]
Secondary Outcome Measures
- Seizure frequency from baseline after ataluren treatment in patients w/ CDKL5 or Dravet from daily seizure diary. [Baseline, 3 months, 6 months, and 1 year]
Other Outcome Measures
- Change from baseline in cognitive behavior measured by Behavior Assessment System for Children [Baseline, 3 months and 6 months]
Clinical and adaptive measures of personality and behavior using the Behavior Assessment System for Children: Third Edition (Sabaz 2003)
- Quality of Life (QOL) as assessed by the Quality of Life in Childhood Epilepsy (QOLCE) (Sabaz 2003) [Baseline, 3 months and 6 months]
Eligibility Criteria
Criteria
Inclusion Criteria:
-
Age ≥ 2 years old and ≤ 12 years old, male or female, at Week 0 (at time informed consent/assent is signed)
-
Documentation of a diagnosis of Dravet syndrome or CDKL5 deficiency resulting from a nonsense mutation in 1 allele, as evidenced by medical records, genetic testing, and the following clinical feature:
- Failure to control seizures despite appropriate trial of 2 or more AEDs at therapeutic doses
- Between 1 to 3 baseline AEDs at stable doses for a minimum for 4 weeks prior to the Baseline visit
- Vagus nerve stimulator (VNS), ketogenic diet, and modified Atkins diet do not count towards this limit but must be unchanged for 3 months prior to enrollment (Baseline).
-
VNS must be on stable settings for a minimum of 3 months prior to the Baseline visit
-
If on ketogenic or modified Atkins diet, must be on stable ratio for a minimum of 3 months prior to the Baseline visit
-
Written consent obtained from the patient or patient's legal representative must be obtained prior to performing any study procedures
-
Minimum of 6 convulsive or drop seizures with duration > 3 seconds over the 4 weeks of diary screening prior to randomization and ≥ 6 convulsive or drop seizures with duration > 3 seconds during the 4 weeks from Screening to Baseline.
Exclusion Criteria:
-
Patient is < 2 years old or ≥ 12 years old
-
Epilepsies associated with genetic disorders other than Dravet syndrome or CDKL5 deficiency
-
Patient has Dravet or CDKL5 genetic mutations that are NOT nonsense mutations
-
Felbatol has been initiated within the past 12 months prior to the Screening Visit
-
Patients who are currently or have participated in clinical trials in the 30 days prior to enrollment (Baseline Visit)
-
Prior or ongoing medical condition (eg, concomitant illness, psychiatric condition), medical history, physical findings, or laboratory abnormality that, in the investigator's opinion, could adversely affect the safety of the patient, makes it unlikely that the course of study drug administration or follow-up would be completed, or could impair the assessment of study results.
-
Ongoing intravenous administration of aminoglycosides or vancomycin.
Contacts and Locations
Locations
| Site | City | State | Country | Postal Code | |
|---|---|---|---|---|---|
| 1 | New York University School of Medicine | New York | New York | United States | 10016 |
Sponsors and Collaborators
- NYU Langone Health
- PTC Therapeutics
Investigators
- Principal Investigator: Orrin Devinsky, MD, NYU
Study Documents (Full-Text)
None provided.More Information
Publications
None provided.- 15-00426